Magazine Article | May 1, 2023

The Hybrid Face Of Biopharma

Source: Life Science Leader

By Matthew Pillar, Editor, Bioprocess Online

As the business of biotech goes, a trend among startups is the blurring of the line between makers of biopharmaceutical assets and those of therapeutic development platforms. We’re increasingly conversing with hybrids that are no less one than the other. There are the academics conceiving an exotic source of cell culture who, to demonstrate their invention, develop a viable therapeutic asset that stands on its own merit. There are the AI-enabled therapeutic developers whose computational success spawns a marketable drug discovery platform. And, in the case of Gain Therapeutics, there’s the developer of a supercomputer-powered target discovery engine that yielded a whopping nine candidates — across four distinct therapeutic areas — along the way.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader